Treatment allocation. This is an open label study. All patients will be treated with BL-1040. Patient eligibility will be established prior to treatment with BL-1040. If a patient discontinues from the study, the patient number will not be reused.
Appears in 7 contracts
Samples: License and Commercialization Agreement (Bellerophon Therapeutics, Inc.), License and Commercialization Agreement (Bellerophon Therapeutics LLC), License and Commercialization Agreement (Bellerophon Therapeutics LLC)
